The DOI matches its Crossref record; 64 of the 68 references it cites were found in a registry or an index.
Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study
Open accessAbstract
Psychotic illnesses show variable responses to treatment. Determining the neurobiology underlying this is important for precision medicine and the development of better treatments. It has been proposed that dopaminergic differences underlie variation in response, with striatal dopamine synthesis capacity (DSC) elevated in responders and unaltered in non-responders. We therefore aimed to test this in a prospective cohort, with a nested case-control comparison. 40 volunteers (26 patients with first-episode psychosis and 14 controls) received an 18 F-DOPA Positron Emission Tomography scan to measure DSC (Ki cer ) prior to antipsychotic treatment. Clinical assessments (Positive and Negative Syndrome Scale, PANSS, and Global Assessment of Functioning, GAF) occurred at baseline and following antipsychotic treatment for a minimum of 4 weeks. Response was defined using improvement in PANSS Total score of >50%. Patients were followed up for at least 6 months, and remission criteria applied. There was a significant effect of group on Ki cer in associative striatum (F (2, 37) = 7.9, p = 0.001). Ki cer was significantly higher in responders compared with non-responders (Cohen’s d = 1.55, p = 0.01) and controls (Cohen’s d = 1.31, p = 0.02). Ki cer showed significant positive correlations with improvements in PANSS-positive ( r = 0.64, p < 0.01), PANSS negative (rho = 0.51, p = 0.01), and PANSS total (rho = 0.63, p < 0.01) ratings and a negative relationship with change in GAF ( r = −0.55, p < 0.01). Clinical response is related to baseline striatal dopaminergic function. Differences in dopaminergic function between responders and non-responders are present at first episode of psychosis, consistent with dopaminergic and non-dopaminergic sub-types in psychosis, and potentially indicating a neurochemical basis to stratify psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When compared using equivalent scanners, patients with psychosis have higher striatal dopamine synthesis capacity than CHR subjects(67).”
From Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis (2020) · cites this paper as [67]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · cited 1×
“Clinical measures were rated at baseline and follow-up using the Positive and Negative Syndrome Scale (PANSS) [26], Global Assessment of Functioning (GAF) [27], and Clinical Global Impression Improvement scale (CGI-I) [28].”
MethodThe clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed · Cited by 2,760
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343 · cited 1×
“[34] remission criteria at 6 months to ascertain remission/ non-remission status.”
BackgroundLaruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226 · cited 1×
““much improved”, respectively) corresponds to clinically significant improvement [32, 33].”
BackgroundHowes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132 · cited 1×
“were required to have taken at least 80% of prescribed doses, in line with recommendations [36].”
ResultSelf-citationKapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090 · cited 2×
“Taken with previous molecular imaging studies showing dopamine D2/3 receptor occupancy by antipsychotics is required for therapeutic response [33, 50], our findings indicate D2/3 receptor blockade is acting to oppose the consequences of presynaptic dopamine dysfunction [51].”
BackgroundResultSelf-citationKahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088 · cited 2×
“[22, 23], including in first-episode psychosis [24].”
BackgroundIncreased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 2×
“and greater synaptic dopamine levels are linked to greater subsequent improvement in psychotic symptoms [15].”
BackgroundInfluential
Research works printed but not linked: 2
- Taylor D, Paton C, Kapur S, (eds). The Maudsley Prescribing Guidelines in Psychiatry. 11th Edition. West Sussex: Wiley-Blackwell: Chichester; 2012.
- Busner J, Targum SD. The clinical global impressions scale. Psychiatry. 2007;4:28–37.
Cited by
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Self-citationBarnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationCandidate biomarkers in psychiatric disorders: state of the field
Abi‐Dargham, A., Moeller, S. J., Ali, F., DeLorenzo, C., Domschke, K., Horga, G., Jutla, A., Kotov, R., Paulus, M. P., Rubio, J. M., et al. (2023) · World Psychiatry · doi:10.1002/wps.21078 · Cited by 372
Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359
“schizophrenia relative to patients with TRS, who, in turn, have a dopamine synthesis capacity similar to healthy controls.(24,53,55) Dopamine synthesis capacity in the striatum has been shown to be lower in patients with TRS who are clozapine-responsive compared with healthy controls or patients without TRS.”
BackgroundSelf-citationHowes, O. D., & Shatalina, E. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.06.017 · Cited by 256
Self-citation
Metadata
- Authors
- Jauhar, S., Veronese, M., Nour, M. M., Rogdaki, M., Hathway, P., Turkheimer, F. E., Stone, J., Egerton, A., McGuire, P., Kapur, S., & Howes, O. D.
- Affiliations
- King's College London (GB)
- Corresponding author
- Howes, Oliver D
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2018-04-20
- Volume
- 24
- Issue
- 10
- Pages
- 1502-1512
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC6331038
- OpenAlex
- W2799407405
- Cited by
- 183
- References
- 68
- Citations by year
- 2026: 12 · 2025: 22 · 2024: 24 · 2023: 13 · 2022: 29 · 2021: 37 · 2020: 16 · 2019: 24 · 2018: 6
- FWCI
- 16.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Wellcome Trust (094849, 094849/Z/10/Z)
- Maudsley Charity
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research (ACF-2016-17-005)
- King's College London
- Servier
- H. Lundbeck A/S
- Medical Research Council (MC- A656-5QD30, MR/N026063/1)
- Cilag
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- first-episode psychosis, treatment response, antipsychotic treatment response, 18F-DOPA PET, dopaminergic activity, striatum, positive and negative symptoms, functional outcome, precision medicine
- MeSH terms
- Adult, Corpus Striatum, Dihydroxyphenylalanine, Dopamine, Female, Humans, Male, Prospective Studies, Psychiatric Status Rating Scales, Psychotic Disorders, Antipsychotic Agents, Cohort Studies, Case-Control Studies, Treatment Outcome, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. https://app.cochat.ai/papers/10.1038/s41380-018-0042-4
- The paper
- Jauhar, S., Veronese, M., Nour, M. M., Rogdaki, M., Hathway, P., Turkheimer, F. E., Stone, J., Egerton, A., McGuire, P., Kapur, S., & Howes, O. D. (2019). Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0042-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.